Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Loans and Notes Receivables Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Ratios

Terns Pharmaceuticals (TERN) Long-Term Debt Issuances (2022 - 2023)

Terns Pharmaceuticals filings provide 2 years of Long-Term Debt Issuances readings, the most recent being $169000.0 for Q4 2023.

Quarterly Long-Term Debt Issuances rose 42.02% to $169000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $288000.0 through Dec 2023, up 142.02% year-over-year, with the annual reading at $410000.0 for FY2023, 68.72% up from the prior year.
Long-Term Debt Issuances hit $169000.0 in Q4 2023 for Terns Pharmaceuticals, up from $119000.0 in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $169000.0 in Q4 2023 and bottomed at $119000.0 in Q4 2022.